PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Gauges a company's financial stability and solvency. Value investors pay close attention to leverage and liquidity risk, ensuring the company has enough cushion to withstand downturns without impairing shareholder value.
0.00
D/E of 0.00 while TRAW has all-equity financing. Bruce Berkowitz would demand higher returns to justify our leverage.
9.80
Net debt 50-75% of TRAW's 14.65. Mohnish Pabrai would check if this competitive advantage in leverage translates to better reinvestment opportunities.
No Data
No Data available this quarter, please select a different quarter.
11.66
Current ratio 1.25-1.5x TRAW's 9.06. Mohnish Pabrai would examine if this strength creates buying power advantages.
No Data
No Data available this quarter, please select a different quarter.